UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer
暂无分享,去创建一个
Kazuo Komamura | Naoyuki Kamatani | Noriko Katori | Yoshiro Saito | Ryuichi Hasegawa | Shiro Kamakura | Masafumi Kitakaze | Jun-ichi Sawada | Teruhiko Yoshida | N. Saijo | N. Kamatani | A. Ohtsu | Yoshiro Saito | M. Kitakaze | S. Ozawa | J. Sawada | S. Kamakura | H. Jinno | R. Hasegawa | K. Komamura | K. Shirao | N. Kaniwa | H. Minami | Teruhiko Yoshida | Nagahiro Saijo | Shogo Ozawa | Hideto Jinno | Kimie Sai | Mayumi Saeki | Nahoko Kaniwa | Kazuyuki Ueno | Yutaka Kitamura | Hironobu Minami | Atsushi Ohtsu | Kuniaki Shirao | K. Sai | K. Ueno | M. Saeki | N. Katori | Y. Kitamura
[1] T. Morisaki,et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm , 2002 .
[2] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[3] S. Wrighton,et al. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.
[4] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[5] Yoshiro Saito,et al. GLUCURONIDATION OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN ( SN-38 ) , AN ACTIVE METABOLITE OF IRINOTECAN ( CPT-11 ) , BY HUMAN UGT 1 A 1 VARIANTS , 2002 .
[6] J. Supko,et al. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[8] Teruhiko Yoshida,et al. Three novel single nucleotide polymorphisms in UGT1A9. , 2003, Drug metabolism and pharmacokinetics.
[9] M. Mori,et al. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. , 2002, Biochemical and biophysical research communications.
[10] J Verweij,et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Yoshiro Saito,et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[12] G. Luo,et al. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. , 2000, Pharmacogenetics.
[13] K. Hayasaka,et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate‐glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese , 1998, Biochemistry and molecular biology international.
[14] A. Di Rienzo,et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. , 2002, Pharmacogenetics.
[15] K. Mizuno,et al. A new enzymatic approach for estimating total and direct bilirubin. , 1988, Clinical biochemistry.
[16] Yoshiro Saito,et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. , 2003, Clinical chemistry.
[17] D Lindhout,et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.
[18] C. Guillemette,et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.
[19] L. Wienkers,et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[20] H. Saka,et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.
[21] Teruhiko Yoshida,et al. Three novel single nucleotide polymorphisms in UGT1A10. , 2002, Drug metabolism and pharmacokinetics.
[22] S. Culine,et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.
[23] S. Ozawa,et al. An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. , 2002, Biomedical chromatography : BMC.
[24] R Judson,et al. The predictive power of haplotypes in clinical response. , 2000, Pharmacogenomics.
[25] B. Burchell,et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.
[26] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[27] J. Verweij,et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] E. Beutler,et al. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Verweij,et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Yoshiro Saito,et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. , 2003, Drug metabolism and disposition: the biological fate of chemicals.